Long-term CaCO
3 treatment was studied in chronic hemodialysis patients. Twenty-three patients, who had been administered Al(OH)
3 before the study, were treated with CaCO
3. When pre-dialysis serum Ca had elevated beyound 5.5 mEq/L, CaCO
3 was reduced and Al(OH)
3 was administered again. Eighteen months later, serum P was controlled, and pre-dialysis serum P was less than 6.5 mg/dl in 13 patients with CaCO
3 alone. ALP levels significantly decreased, and serum aluminum was remarkably lowered in the patients who had discontinued Al(OH)
3. In patients who resumed Al(OH)
3, ALP levels rose after the resumption. The changes in serum aluminum concentration 48 hours after the infusion of 2 gms of desferrioxamine were significantly lower in patients who had discontinued Al(OH)
3 than in patients who resumed it, whereas no differences were noted between the two groups in dialysis duration and total amount of administered Al(OH)
3. These data indicate that CaCO
3 is an effective P-binder, which not only stops the progression of silent osteopathy presumably caused by oral intake of Al(OH)
3, but also may ameliorate the bone changes. However, further efforts will be necessary to control serum Ca within normal range, since the long term use of CaCO
3 induced hypercalcemia in almost half of the patients.
View full abstract